Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease LA JOLLA, Calif. , May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326 Reinitiated Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD Closed $26 Million Second Tranche of Private Financing LA JOLLA, Calif. , March 12, 2020 /PRNewswire/ -- Regulus Therapeutics
LA JOLLA, Calif. , Feb. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it initiated dosing of the second cohort of its Phase 1 multiple
Regulus Plans to Re-Initiate Clinical Studies in Q1 2020 Milestone for Second Tranche of Private Financing of Approximately $25.1 Million Achieved LA JOLLA, Calif. , Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
LA JOLLA, Calif. , Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326 Appointment of Cris Calsada as New Chief Financial Officer LA JOLLA, Calif. , Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.
LA JOLLA, Calif. , Oct. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS) , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that it presented preclinical data that identifies RGLS4326, a
LA JOLLA, Calif. , Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled, "Discovery
LA JOLLA, Calif. , Sept. 3, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
LA JOLLA, Calif. , Aug. 29, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
